Philippe Montravers1, Matteo Bassetti2. 1. Département d'anesthésie-réanimation, CHU Bichat-Claude Bernard, APHP, Université Paris Diderot, PRESS Sorbonne Cité, INSERM UMR 1152, Paris, France. 2. Infectious Diseases Division, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
Abstract
PURPOSE OF REVIEW: The worldwide spread of extended-spectrum beta-lactamase (ESBL)-producing bacteria, the overuse of carbapenems, the emergence of carbapenemase-producing organisms and the growing importance of multidrug-resistant and/or extended drug-resistant strains have totally changed prescribers' habits, leading to very few treatment options in many cases. Beta-lactam/beta-lactamase inhibitor (BLBLI) combinations should be considered as an alternative to carbapenems for treating ESBL-producing bacteria and Pseudomonas aeruginosa infections. The purpose of this study was to provide insight concerning the patients who would constitute ideal candidates to receive these new BLBLI combinations. RECENT FINDINGS: Ceftolozane/tazobactam and ceftazidime/avibactam are the first drugs constituting the use of new beta-lactamase inhibitors. Ceftolozane/tazobactam is the drug of choice for treating MDR/XDR P. aeruginosa infections. Ceftazidime/avibactam is the best drug available for treating KPC and OXA-48 carbapenemase-producing Enterobacteriaceae. Ceftolozane/tazobactam and ceftazidime/avibactam are both carbapenem-sparing agents for treating ESBL-producing Enterobacteriaceae. The role of carbapenem/inhibitors remains to be clarified. SUMMARY: Each BLBLI combination has distinctive specificities and limitations that need to be investigated cautiously. Randomized trials will play a key role in defining the best strategies. Infection control measures and prompt diagnosis remain fundamental to prevent dissemination of MDR pathogens in healthcare settings and to optimize early antimicrobial treatment.
PURPOSE OF REVIEW: The worldwide spread of extended-spectrum beta-lactamase (ESBL)-producing bacteria, the overuse of carbapenems, the emergence of carbapenemase-producing organisms and the growing importance of multidrug-resistant and/or extended drug-resistant strains have totally changed prescribers' habits, leading to very few treatment options in many cases. Beta-lactam/beta-lactamase inhibitor (BLBLI) combinations should be considered as an alternative to carbapenems for treating ESBL-producing bacteria and Pseudomonas aeruginosa infections. The purpose of this study was to provide insight concerning the patients who would constitute ideal candidates to receive these new BLBLI combinations. RECENT FINDINGS:Ceftolozane/tazobactam and ceftazidime/avibactam are the first drugs constituting the use of new beta-lactamase inhibitors. Ceftolozane/tazobactam is the drug of choice for treating MDR/XDR P. aeruginosa infections. Ceftazidime/avibactam is the best drug available for treating KPC and OXA-48 carbapenemase-producing Enterobacteriaceae. Ceftolozane/tazobactam and ceftazidime/avibactam are both carbapenem-sparing agents for treating ESBL-producing Enterobacteriaceae. The role of carbapenem/inhibitors remains to be clarified. SUMMARY: Each BLBLI combination has distinctive specificities and limitations that need to be investigated cautiously. Randomized trials will play a key role in defining the best strategies. Infection control measures and prompt diagnosis remain fundamental to prevent dissemination of MDR pathogens in healthcare settings and to optimize early antimicrobial treatment.
Authors: Jeffrey R Strich; Emily Ricotta; Sarah Warner; Yi Ling Lai; Cumhur Y Demirkale; Samuel F Hohmann; Chanu Rhee; Michael Klompas; Tara Palmore; John H Powers; John P Dekker; Jennifer Adjemian; Roland Matsouaka; Christopher W Woods; Robert L Danner; Sameer S Kadri Journal: Clin Infect Dis Date: 2021-02-16 Impact factor: 9.079
Authors: Gerardo Aguilar; Rafael Ferriols; Sara Martínez-Castro; Carlos Ezquer; Ernesto Pastor; José A Carbonell; Manuel Alós; David Navarro Journal: Crit Care Date: 2019-04-26 Impact factor: 9.097
Authors: Paulina Paprocka; Bonita Durnaś; Angelika Mańkowska; Karol Skłodowski; Grzegorz Król; Magdalena Zakrzewska; Michał Czarnowski; Patrycja Kot; Kamila Fortunka; Stanisław Góźdź; Paul B Savage; Robert Bucki Journal: Infect Drug Resist Date: 2021-12-25 Impact factor: 4.003
Authors: Matteo Bassetti; Souha S Kanj; Pattarachai Kiratisin; Camilla Rodrigues; David Van Duin; María Virginia Villegas; Yunsong Yu Journal: JAC Antimicrob Resist Date: 2022-09-13